Contributory Role of Five Common Polymorphisms of RAGE and APE1 Genes in Lung Cancer among Han Chinese

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Pan, Hongming ^a,b   Niu, Wenquan ^c   He, Lan ^b   Wang, Bin ^b   Cao, Jun ^b   Zhao, Feng ^a   Liu, Ying ^a   Li, Shen ^a   Wu, Huijian ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b QIQIHAR MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; LIGASE;

ADULT; ALLELE; APE1 GENE; ARTICLE; CANCER RISK; CHINESE; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; RAGE GENE; VALIDATION PROCESS;

ANTIGENS, NEOPLASM; ASIAN CONTINENTAL ANCESTRY GROUP; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; POLYMORPHISM, GENETIC;

EID: 84880080159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069018     Document Type: Article

References (25)

1. Guo S, Li X, Gao M, Li Y, Song B, et al. (2013) The Relationship between XRCC1 and XRCC3 Gene Polymorphisms and Lung Cancer Risk in Northeastern Chinese. PLoS One 8: e56213.
2. Moore JH, Williams SM, (2009) Epistasis and its implications for personal genetics. Am J Hum Genet 85: 309-320.
3. de Bittencourt Pasquali MA, Gelain DP, Zeidan-Chulia F, Pires AS, Gasparotto J, et al. (2013) Vitamin A (retinol) downregulates the receptor for advanced glycation endproducts (RAGE) by oxidant-dependent activation of p38 MAPK and NF-kB in human lung cancer A549 cells. Cell Signal 25: 939-954.
4. Jing RR, Cui M, Sun BL, Yu J, Wang HM, (2010) Tissue-specific expression profiling of receptor for advanced glycation end products and its soluble forms in esophageal and lung cancer. Genet Test Mol Biomarkers 14: 355-361.
5. Yang ZZ, Li MX, Zhang YS, Xiang DB, Dai N, et al. (2010) Knock down of the dual functional protein apurinic/apyrimidinic endonuclease 1 enhances the killing effect of hematoporphrphyrin derivative-mediated photodynamic therapy on non-small cell lung cancer cells in vitro and in a xenograft model. Cancer Sci 101: 180-187.
6. Lu J, Zhang S, Chen D, Wang H, Wu W, et al. (2009) Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility. FASEB J 23: 3459-3469.
7. Buckley ST, Ehrhardt C, (2010) The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010: 917108.
8. Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, et al. (2004) Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells 9: 165-174.
9. Schenk S, Schraml P, Bendik I, Ludwig CU, (2001) A novel polymorphism in the promoter of the RAGE gene is associated with non-small cell lung cancer. Lung Cancer 32: 7-12.
10. Jing R, Cui M, Wang J, Wang H, (2010) Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 57: 55-61.
11. Bartling B, Demling N, Silber RE, Simm A, (2006) Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am J Respir Cell Mol Biol 34: 83-91.
12. Stram DO, Leigh Pearce C, Bretsky P, Freedman M, Hirschhorn JN, et al. (2003) Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 55: 179-190.
13. Pattin KA, White BC, Barney N, Gui J, Nelson HH, et al. (2009) A computationally efficient hypothesis testing method for epistasis analysis using multifactor dimensionality reduction. Genet Epidemiol 33: 87-94.
14. Hahn LW, Ritchie MD, Moore JH, (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19: 376-382.
15. Ritchie MD, Motsinger AA, (2005) Multifactor dimensionality reduction for detecting gene-gene and gene-environment interactions in pharmacogenomics studies. Pharmacogenomics 6: 823-834.
16. Wei W, He XF, Qin JB, Su J, Li SX, et al. (2012) Association between the OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep 39: 11249-11262.
17. Yokota J, Shiraishi K, Kohno T, (2010) Genetic basis for susceptibility to lung cancer: Recent progress and future directions. Adv Cancer Res 109: 51-72.
18. Cardon LR, Bell JI, (2001) Association study designs for complex diseases. Nat Rev Genet 2: 91-99.
19. Sha Q, Zhang S, (2011) A test of Hardy-Weinberg equilibrium in structured populations. Genet Epidemiol 35: 671-678.
20. Gui J, Andrew AS, Andrews P, Nelson HM, Kelsey KT, et al. (2010) A simple and computationally efficient sampling approach to covariate adjustment for multifactor dimensionality reduction analysis of epistasis. Hum Hered 70: 219-225.
21. Moore JH, (2010) Detecting, characterizing, and interpreting nonlinear gene-gene interactions using multifactor dimensionality reduction. Adv Genet 72: 101-116.
22. Gu M, Dong X, Zhang X, Wang X, Qi Y, et al. (2012) Strong association between two polymorphisms on 15q25.1 and lung cancer risk: a meta-analysis. PLoS One 7: e37970.
23. Guo S, Li X, Gao M, Kong H, Li Y, et al. (2012) Synergistic association of PTGS2 and CYP2E1 genetic polymorphisms with lung cancer risk in northeastern Chinese. PLoS One 7: e39814.
24. Ihsan R, Chauhan PS, Mishra AK, Yadav DS, Kaushal M, et al. (2011) Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLoS One 6: e29431.
25. Moore JH, Ritchie MD, (2004) STUDENTJAMA. The challenges of whole-genome approaches to common diseases. JAMA 291: 1642-1643.